Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fabrizi, F.
Right arrow Articles by Locatelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fabrizi, F.
Right arrow Articles by Locatelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1999) 14: 2079-2081
© 1999 European Renal Association-European Dialysis and Transplant Association

Editorial Comments

Combination of interferon alpha and ribavirin in the treatment of hepatitis C: implications for the clinical nephrologist

Fabrizio Fabrizi and Francesco Locatelli

Nephrology and Dialysis Division, Azienda Ospedale di Lecco, Lecco, Italy

Correspondence and offprint requests to: Fabrizio Fabrizi, Nephrology and Dialysis Division, Azienda Ospedale di Lecco, via Ghislanzoni 22, I-23900 Lecco, Italy. E-mail nefrolec@tin.it.

Introduction

Hepatitis C virus (HCV) infection is very frequent among patients with end-stage renal disease (ESRD). Recent studies have shown that HCV may increase the risk for death in the haemodialysis (HD) population and appears to have a deleterious impact on long-term graft and patient survival among renal transplant recipients [1]. Furthermore, HCV results in a significantly increased risk of kidney allograft failure and death among kidney–pancreas transplant patients.

While important advances have been made in preventing hepatitis C, therapy for this disease among ESRD patients remains unsatisfactory. In fact, valid animal models and effective cell culture systems with which to study HCV are lacking.

At present, the most important therapy for hepatitis C in ESRD patients is interferon (IFN), but it is expensive and has limited efficacy and safety. Alternative approaches based on new formulations of IFN are currently under way and combinations of IFN with nucleotide analogues . . . [Full Text of this Article]

Interferon treatment of HCV in ESRD

Novel treatments for HCV in ESRD

Combination of IFN-{alpha} and ribavirin

Conclusions

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
A. C. I. T. L. Tan, J. T. Brouwer, P. Glue, R. van Leusen, R. H. Kauffmann, S. W. Schalm, R. A. de Vries, and B. Vroom
Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study
Nephrol. Dial. Transplant., January 1, 2001; 16(1): 193 - 195.
[Full Text] [PDF]